Skip to main content
IDXX
NASDAQ Life Sciences

IDEXX 10-Q Details Q3 EPS of $4.01, $934M Nine-Month Net Income and $250M CoVetAI Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$670
Mkt Cap
$52.913B
52W Low
$500.61
52W High
$769.98
52W Position info
34% above low
Off High info
13% below high
Rel. Volume info
3.5× avg
Market data snapshot near publication time

IDXX sits 34% above its 52-week low of $500.61 on elevated volume (3.5× avg).

Summary

IDEXX's Q3 10-Q confirms EPS of $4.01 on $1.214B revenue with margins expanding, nine-month operating cash flow of $1.063B, and quantifies the ~$250M CoVetAI acquisition closed September 15.


Key Events · Earnings and Guidance · IDXX

  • Q3 EPS $4.01 on $1.214B Revenue

    Revenue rose 9.9% to $1,214,237 thousand from $1,105,239 thousand, with net income of $317,145 thousand and diluted EPS of $4.01 versus $3.40 a year ago.

  • Gross Margin Expands 110 Basis Points

    Gross profit of $764,298 thousand was 62.9% of revenue versus 61.8% prior year, driven by VetLab consumable volume, mix and net price realization; income from operations rose 13.4% to $402,348 thousand.

  • Nine-Month Operating Cash Flow $1.063B

    Net cash from operations reached $1,063,127 thousand, up $237,082 thousand year over year, funding $804,698 thousand of open-market buybacks and the CoVetAI acquisition.

  • CoVetAI Deal Priced at ~$250M

    The September 15, 2026 acquisition carried total consideration of approximately $250 million including a $20 million estimated contingent payment, with $230 million allocated to goodwill and $25 million to technology and customer-relationship intangibles.


Analysis · IDXX · Life Sciences

The headline numbers were already out this morning via the 8-K and wires, but the 10-Q is where the full picture sits: Q3 revenue of $1.214B (+9.9%) with gross margin up 110 bps to 62.9%, and nine-month operating cash flow of $1.063B, up $237M year over year. It also puts hard numbers on the CoVetAI acquisition closed September 15 — roughly $250M including a $20M contingent payment, with $230M landing in goodwill — and confirms the buyback is running hard at $804.7M of open-market repurchases over nine months. The balance sheet stays conservative: $474M drawn on the credit facility against $773.2M of remaining availability and a 0.5-to-1 leverage ratio.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IDXX was trading at $670.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.9B. The 52-week trading range was $500.61 to $769.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IDXX - Latest Insights

IDXX
Nov 02, 2026, 11:45 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $659.20
Real-time Price: $700.65 info
Change: +$41.45 (+6%) info
Market Cap: $55.202B info
IDXX
Nov 02, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $555.00
Real-time Price: $700.65 info
Change: +$145.65 (+26%) info
Market Cap: $55.202B info
IDXX
Nov 02, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $544.00
Real-time Price: $700.65 info
Change: +$156.65 (+29%) info
Market Cap: $55.202B info
IDXX
Sep 16, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $505.26
Real-time Price: $700.65 info
Change: +$195.39 (+39%) info
Market Cap: $55.202B info
IDXX
Aug 04, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $588.09
Real-time Price: $700.65 info
Change: +$112.56 (+19%) info
Market Cap: $55.202B info